Alnylam Pharmaceuticals Inc (ALNY)vsTG Therapeutics Inc (TGTX)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
TGTX
TG Therapeutics Inc
$31.82
+5.29%
HEALTHCARE · Cap: $4.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 503% more annual revenue ($3.71B vs $616.29M). TGTX leads profitability with a 72.6% profit margin vs 8.5%. TGTX trades at a lower P/E of 10.9x. TGTX earns a higher WallStSmart Score of 63/100 (C+).
ALNY
Hold49
out of 100
Grade: D+
TGTX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
-53.0%
Fair Value
$18.84
Current Price
$31.82
$12.98 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Every $100 of equity generates 103 in profit
Keeps 73 of every $100 in revenue as profit
Revenue surging 78.0% year-over-year
Strong operational efficiency at 26.2%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Expensive relative to growth rate
Earnings declined 6.1%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : TGTX
The strongest argument for TGTX centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 72.6% and operating margin at 26.2%. Revenue growth of 78.0% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.86 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (63/100 vs 49/100), backed by strong 72.6% margins and 78.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?